These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 33126605)

  • 21. Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand.
    Aye PS; Tin Tin S; McKeage MJ; Khwaounjoo P; Cavadino A; Elwood JM
    BMC Cancer; 2020 Jul; 20(1):658. PubMed ID: 32664868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
    Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CT texture analysis of lung adenocarcinoma: can Radiomic features be surrogate biomarkers for EGFR mutation statuses.
    Mei D; Luo Y; Wang Y; Gong J
    Cancer Imaging; 2018 Dec; 18(1):52. PubMed ID: 30547844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Roles of highly expressed PAICS in lung adenocarcinoma.
    Zhou S; Yan Y; Chen X; Wang X; Zeng S; Qian L; Wei J; Yang X; Zhou Y; Gong Z; Xu Z
    Gene; 2019 Apr; 692():1-8. PubMed ID: 30641222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic implication of EGFR mutation status and subtype in resected lung adenocarcinoma patients irrespective of therapy.
    Li R; Li Q; Lin S; Li W; Yu L; Wang L; Dong X; Yu L; Li S; Liu W; Li B
    Clin Transl Oncol; 2019 Mar; 21(3):298-303. PubMed ID: 30022385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis.
    Sun Y; Wu M; Zhou M; Luo X; Guo Y; Bai H; Zhang Z; Tian W; Wang X; Bai Y; Zhu X; Pan H; Deng Y; Hu H; Xia J; Hao X; Han L; Wei M; Liu Y; Zeng M
    BMC Cancer; 2020 Jul; 20(1):646. PubMed ID: 32660443
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Li JP; Hsieh MJ; Chou YE; Chao YH; Tsao TC; Yang SF
    Int J Environ Res Public Health; 2020 Apr; 17(9):. PubMed ID: 32344833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathologic characteristics and EGFR mutations in lung cancer patients aged below 45 years.
    Xia J; Li H; Ji Y; Mi C; Chen G; Li P; Zhang R; Chen W; Wang J
    Curr Probl Cancer; 2019 Aug; 43(4):363-370. PubMed ID: 30522775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of EGFR 1 Gene Alteration and their Association with Lung Adenocarcinoma Patients.
    Ali Beg MM; Fahdil SR; Yadav P; Shukla KK; Mohan A; Saxena A
    Asian Pac J Cancer Prev; 2019 Mar; 20(3):825-830. PubMed ID: 30912007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EEF1A2 and ERN2 could potentially discriminate metastatic status of mediastinal lymph node in lung adenocarcinomas harboring EGFR 19Del/L858R mutations.
    Xia L; Wang H; Xiao H; Lan B; Liu J; Yang Z
    Thorac Cancer; 2020 Oct; 11(10):2755-2766. PubMed ID: 32881299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
    Takeda M; Sakai K; Hayashi H; Tanaka K; Haratani K; Takahama T; Kato R; Yonesaka K; Nishio K; Nakagawa K
    Lung Cancer; 2020 Jan; 139():28-34. PubMed ID: 31710890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.
    Lee JK; Lee J; Kim S; Kim S; Youk J; Park S; An Y; Keam B; Kim DW; Heo DS; Kim YT; Kim JS; Kim SH; Lee JS; Lee SH; Park K; Ku JL; Jeon YK; Chung DH; Park PJ; Kim J; Kim TM; Ju YS
    J Clin Oncol; 2017 Sep; 35(26):3065-3074. PubMed ID: 28498782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.
    Arrieta O; Ramírez-Tirado LA; Caballé-Perez E; Mejia-Perez A; Zatarain-Barrón ZL; Cardona AF; Lozano-Ruíz F; Segura-González M; Cruz-Rico G; Maldonado F; Rosell R
    Thorac Cancer; 2020 Apr; 11(4):1026-1037. PubMed ID: 32072746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
    Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
    Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of E-cadherin gene polymorphisms and epidermal growth factor receptor mutation in lung adenocarcinoma.
    Huang CY; Hsieh MJ; Liu TC; Chiang WL; Liu MC; Yang SF; Tsao TC
    Int J Med Sci; 2018; 15(8):765-770. PubMed ID: 30008585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of WW Domain-Containing Oxidoreductase Gene Polymorphism on Clinicopathological Characteristics of Patients with EGFR Mutant Lung Adenocarcinoma in Taiwan.
    Li JP; Chang JT; Ju PC; Hsieh MH; Chao YH; Tsao TC; Hsieh MJ; Yang SF
    Int J Environ Res Public Health; 2021 Dec; 18(24):. PubMed ID: 34948746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of localization of epidermal growth factor receptor in lung adenocarcinoma.
    Wang JL; Fang CL; Tzeng YT; Hsu HL; Lin SE; Yu MC; Bai KJ; Wang LS; Liu HE
    J Biomed Sci; 2018 Jun; 25(1):53. PubMed ID: 29950164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of cytokines levels with epidermal growth factor receptor mutation in lung cancer patients.
    Gaur P; Bhattacharya S; Kant S; Kushwaha RAS; Singh G; Pandey S
    J Cancer Res Ther; 2020; 16(4):811-815. PubMed ID: 32930123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.